- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07951749
Evaluating Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE) (BESAFE)
An Open Label, Single Arm, Explorative Trial to Evaluate Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE)
The primary aim of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with Acquired Angioedema (AAE-C1-INH).
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This study aims to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with AAE-C1-INH and to evaluate its safety profile. This is an open label single arm study. Each eligible subject who consents to participate in the study will receive 24 weeks (168 days) of oral Berotralstat (150 mg). All subjects will undergo a screening period (including a prospective AAE-C1-INH attack run- in period between 28 and 56 days) and will then enter the treatment phase. During this phase, there will be follow-up assessments (at 29, 85 and 169 days) including physical examination, vital signs assessment, blood and urine analysis, 12-lead ECG and PROMs evaluation. Details on AAE-C1-INH attacks, concomitant medications and adverse events will be collected through the course of the study.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Andrea Zanichelli, PhD, MD
- Número de teléfono: *39) 0252774690
- Correo electrónico: andrea.zanichelli@unimi.it
Ubicaciones de estudio
-
-
-
Palermo, Italia, 90146
- A.O. "Ospedali Riuniti Villa Sofia-Cervello"
-
Contacto:
- Francesco Arcoleo, MD
- Número de teléfono: (+39) 0916802882
- Correo electrónico: farcoleo@villasofia.it
-
-
Milan
-
Milan, Milan, Italia, 20157
- Ospedale Luigi Sacco
-
Contacto:
- Antonio Gidaro, MD
- Número de teléfono: (+39) 0239042516
- Correo electrónico: gidaro.antonio@asst-fbf-sacco.it
-
San Donato Milanese, Milan, Italia, 20097
- IRCCS Policlinico San Donato
-
Contacto:
- Andrea Zanichelli, PhD, MD
- Número de teléfono: (+39) 0252774690
- Correo electrónico: andrea.zanichelli@unimi.it
-
-
Naples
-
Naples, Naples, Italia, 80131
- Università degli Studi di Napoli Federico II
-
Contacto:
- Giuseppe Spadaro, MD
- Número de teléfono: (+39) 0817462279
- Correo electrónico: spadaro@unina.it
-
-
Padua
-
Padova, Padua, Italia, 35128
- Azienda Ospedale-Università di Padova
-
Contacto:
- Mauro Cancian, PhD, MD
- Número de teléfono: (+39) 0498214452
- Correo electrónico: mcancian@unipd.it
-
-
Rome
-
Roma, Rome, Italia, 00133
- Fondazione PTV Policlinico Tor Vergata
-
Contacto:
- Paola Triggianese, MD
- Número de teléfono: (+39) 0620901
- Correo electrónico: paola.triggianese@ptvonline.it
-
-
Turin
-
Torino, Turin, Italia, 10128
- AO Ordine Mauriziano di Torino
-
Contacto:
- Luisa Brussino, MD
- Número de teléfono: (+39) 0115082410
- Correo electrónico: lbrussiono@mauriziano.it
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Males and non-pregnant, non-lactating females ≥ 18 years of age
-
Able to provide written, informed consent.
-
Subject weight of ≥ 40 kg
-
A clinical diagnosis of AAE is defined from the following criteria:
-
Recurrent angioedema without wheals
-
No family history of angioedema and/or C1-INH deficiency
-
C1-inhibitor activity level of <50% of normal and at least 1 of the following:
- Age at least 40 years at reported onset of first angioedema symptoms
- Reduced C1q level (below the lower limit of normal), recognizing that normal C1q levels do not exclude the diagnosis of AAE. Absence of a pathogenic variant in the SERPING1 gene encoding for the C1-inhibitor protein.
- Serologic confirmation of anti-C1-inhibitor antibodies.
-
-
Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE (icatibant, plasmaderived C1-INH).
-
The subject must have at least 2 AAE attacks which meet all the requirements below during the run-in period of 28 days. In case of not recurrence of 2 attacks in 28 days or attacks do not meet all the requirements below, the run-in period will be extended to a maximum of 56 days from the Screening visit:
- The attacks are unique, which is defined as an attack that does not begin within 48 hours of the end of a previous attack.
- The attacks must include symptoms of swelling. Symptoms of swelling, in addition to visible swelling, may also include symptoms in the oropharyngeal or abdominal regions which are indicative of internal swelling.
- The attacks are confirmed by the Investigator to be AAE attacks. Subjects will be contacted within 2 business days of the attack to discuss the attack, any queries on the entered data in the diary, as applicable.
-
In the opinion of the Investigator, the subject is expected to adequately comply with all required study procedures for the duration of the study. The subject must demonstrate adequate compliance with all study procedures required from the screening visit, including diary recording of HAE attacks beginning at the screening visit. Women of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of contraception, throughout the study and for the protocol-defined period after the last dose of the investigational medicinal product (IMP). Acceptable highly effective methods include combined (estrogen- and progestogen-containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine devices (IUDs), intrauterine hormone-releasing systems (IUSs), bilateral tubal occlusion, vasectomized partner (provided he is the sole sexual partner), and true sexual abstinence when this is the participant's usual and preferred lifesty.
Exclusion Criteria:
-
Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study or increases the risk to the subject by participating in the study
-
Concurrent diagnosis of any other type of recurrent angioedema
-
Any abnormal clinical, laboratory or urinalysis parameter at screening that, in the opinion of the Investigator or any contraindication describe in berotralstat SmPC
-
Known hypersensitivity to the active substance of berotralstat or to any of its excipients
-
Current treatment with any long-term prophylactic therapy intended for the prevention of angioedema attacks, unless the required washout period has been completed before the start of the run-in period. Required washout periods are as follows:
- plasma-derived or recombinant C1 inhibitor used for long-term prophylaxis: 14 days;
- lanadelumab: 28 days;
- berotralstat or any other oral plasma kallikrein inhibitor: 28 days;
- attenuated androgens (e.g., danazol): 28 days;
- tranexamic acid: 28 days;
- any other investigational or approved long-term prophylactic treatment for angioedema: at least 28 days, or 5 half-lives, whichever is longer.
Use of approved on-demand (rescue) therapies for the treatment of acute angioedema attacks (e.g., icatibant or plasma-derived C1 inhibitor) is permitted throughout the study, including during the run-in period and the treatment period, according to standard clinical practice.
-
Pregnant women
-
Patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) in alignment with SmPC requirement
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Berotralstat Treatment
Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study. |
Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Berotralstat Effectiveness
Periodo de tiempo: Up to 24 weeks.
|
The primary objective of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with AAE-C1-INH. The primary efficacy endpoint is the change in the monthly HAE attacks rate, from week 1 to week 24 of treatment compared to attack rate during the run-in period. |
Up to 24 weeks.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Berotralstat Safety
Periodo de tiempo: Up to 24 weeks.
|
The safety objective is to evaluate the proportion of patients with adverse events (AEs) including treatment-emergent serious adverse events (TESAEs). |
Up to 24 weeks.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Andrea Zanichelli, PhD, MD, IRCCS Policlinico S. Donato
Publicaciones y enlaces útiles
Publicaciones Generales
- Farkas H, Peter JG, Stobiecki M, Anderson J, Aygoren-Pursun E, Hagin D, Jesenak M, Kessel A, Kiani-Alikhan S, Kinaciyan T, Manning M, Reshef A, Wu A, Iocca HA, Johnston DT, Noble L, Tomita D, Banerji A. Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final results. Ann Allergy Asthma Immunol. 2025 Sep;135(3):311-319.e6. doi: 10.1016/j.anai.2025.06.004. Epub 2025 Jun 7.
- Zuraw B, Lumry WR, Johnston DT, Aygoren-Pursun E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlikova J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9. doi: 10.1016/j.jaci.2020.10.015. Epub 2020 Oct 21.
- Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E, Banerji A, Bara NA, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Busse PJ, Bygum A, Caballero T, Cancian M, Castaldo A, Cohn DM, Csuka D, Farkas H, Gompels M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Kang HR, Kaplan AP, Katelaris C, Kiani-Alikhan S, Lei WT, Lockey R, Longhurst H, Lumry WR, MacGinnitie A, Malbran A, Martinez Saguer I, Matta JJ, Nast A, Nguyen D, Nieto-Martinez SA, Pawankar R, Peter J, Porebski G, Prior N, Reshef A, Riedl M, Ritchie B, Rafique Sheikh F, Smith WB, Spaeth PJ, Stobiecki M, Toubi E, Varga LA, Weller K, Zanichelli A, Zhi Y, Zuraw B, Craig T. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022 Jul;77(7):1961-1990. doi: 10.1111/all.15214. Epub 2022 Feb 3.
- Castelli R, Zanichelli A, Cicardi M, Cugno M. Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. Crit Rev Oncol Hematol. 2013 Sep;87(3):323-32. doi: 10.1016/j.critrevonc.2013.02.004. Epub 2013 Mar 13.
- Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol. 2014 Aug;14(4):354-62. doi: 10.1097/ACI.0000000000000082.
- Cicardi M, Zanichelli A. The acquired deficiency of C1-inhibitor: lymphoproliferation and angioedema. Curr Mol Med. 2010 Jun;10(4):354-60. doi: 10.2174/156652410791317066.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- BESAFE
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .